Cellular Therapeutics (United Kingdom)

Efficacy and tolerability of venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukemia – real-world analysis of Polish adult leukemia study group

We collected clinical data on 363 patients with relapsed/refractory chronic lymphocytic leukemia (RR-CLL) treated with venetoclax-rituximab (VR) in a real-world setting. The median age was 69.5 years (range, 32.5–91.6 years), and the median number of prior lines of therapy was 2...